Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Chronic Progressive EDSS of 0.0 5. 2. Multiple Sclerosis according to 2010 revised Mc Donald and less than 15 years of evolution of disease. 3. Patients with Active relapsing remitting multiple sclerosis (RRMS) (more than 1 relapse in last year and/or occurrence of ≥3 new T2 lesions or Gd positive) who not wish to be treated with current therapies Low activity RRMS (1 relapse in last year or occurrence of 1 or 2 T2 lesions or Gd positive) without treatment Progressive forms of MS with activity (at least 1 relapse in last year or occurrence 1 or 2 T2 lesions or Gd positive) RRMS treated with interferon beta (Additional group) 4. T cell proliferation to the pool of myelin peptides against which is to induce immune tolerance: Myelin basic protein (MBP)13-32, MBP83-99, MBP111-129, MBP146-170, proteolipid protein (PLP) 139-154, Myelin oligodendrocyte glycoprotein (MOG)1-20, MOG35 -55). 5. Adequate peripheral venous access. 6. Signed informed consent  Use of corticosteroids during the prior 4 weeks. 2. Use of interferon beta -in patients who is retired by inefficiency or other causes- and glatiramer acetate in the 4 weeks prior. 3. Use of fingolimod, dimethylfumarate, natalizumab, immunoglobulins or plasmapheresis at 12 weeks; and teriflunomide in the 15 weeks prior. 4. Use of azathioprine, mitoxantrone, rituximab, methotrexate, cyclophosphamide, cyclosporine, alemtuzumab or other immunosuppressive drug, except corticosteroids, at any time. 5. Bone marrow or stem cell transplant at any time. 6. Relapse during the month prior of starting treatment. If it appears and the patient meets the must wait long enough until the end of the 30 days free of relapse. If corticosteroids are administered, the MRI performed during this period should not be considered, and a new MRI will be performed at 4 weeks after administration of corticosteroids. 7. Pregnancy or planning pregnancy within the next 12 months and breastfeeding. 8. Fertile patients who are not using an appropriate method of contraception. If the patient is menopausal or sterile it must be documented in the medical record. 9. Abusing drugs or alcohol. 10. Inability to undergo MRI evaluations. 11. Seropositivity for HIV, hepatitis B or C and/or syphilis. 12. History of oncological disease. 13. Clinically relevant concomitant disease: cardiac, pulmonary, neurological, renal or other major illness. 14. Splenectomy. 15. Dementia, psychiatric problems or other comorbidities that might interfere protocol compliance. 16. To be participating in another clinical study or to have participated in one in the last 3 months